[Featured Stock] JinMatrix Develops Two Monkeypox Diagnostic Kits...27%↑

On the 27th of last month, Kim Young-hwan, Director of the Trauma Center, who will treat a monkeypox patient, is filling out a preliminary examination form before vaccination at the main building of the National Medical Center in Jung-gu, Seoul. Photo by Moon Ho-nam munonam@

[Asia Economy Reporter Minji Lee] Jin Matrix is surging ahead of the market close.

At 2:59 PM on the 6th, Jin Matrix was trading at 7,620 KRW, up 27.42% from the previous trading day. The stock price, which showed a sharp rise in the afternoon, even touched the daily upper limit price of 7,700 KRW during the session.

The news that the company developed a PCR-based monkeypox diagnostic kit is believed to have stimulated investor sentiment. On the same day, the company announced the completion of development for two new monkeypox diagnostic kit products. The developed products are 'Neoplex MPX,' which diagnoses monkeypox infection, and 'Neoplex MPX-VZV,' which can simultaneously differentiate and diagnose monkeypox and shingles.

The company stated, "The new monkeypox diagnostic kit products reduce the testing time to around 40 minutes, improving speed and convenience compared to existing products that require 1 to 2 hours for testing, while also achieving high testing accuracy."